RARE Next Earnings Date Notes

— Ultragenyx Pharmaceutical (NASDAQ: RARE) is a biopharmaceutical company focused on developing & commercializing novel products for rare & ultra-rare genetic diseases, an area often underserved by larger pharmaceutical firms. Its portfolio includes approved therapies like Crysvita (for XLH & TIO), Mepsevii (for MPS VII), & Dojolvi (for LC-FAOD), with a robust pipeline targeting additional rare metabolic, neurological, & genetic conditions. For investors listening to the next earnings call, key business metrics to monitor include product net sales (especially sequential & year-over-year growth in Crysvita and Dojolvi), pipeline progress (noting clinical trial milestones, regulatory updates, & potential product launches), research & development (R&D) expense trends, and cash runway or burn rate. Keeping an eye on patient population growth, reimbursement dynamics, & partnership updates is also critical. These metrics will provide insight into both near-term commercial execution & the company’s ability to sustain long-term growth in the competitive rare disease landscape. The next projected earnings date for RARE is 11/3/2026 after close (stay tuned for a confirmed earnings date once announced).

Ultragenyx Pharmaceutical Next Earnings Date FAQ

On this page we presented the Ultragenyx Pharmaceutical Next Earnings Date information for Ultragenyx Pharmaceutical along with recent past earnings dates. For Q2 of 2026, RARE reported earnings of -0.900/share, with the earnings report taking place on 8/4/2026. For Q1 of 2026, RARE reported earnings of -1.840/share, with the earnings report taking place on 5/5/2026. For Q4 of 2025, RARE reported earnings of -1.290/share, with the earnings report taking place on 2/12/2026. For Q3 of 2025, RARE reported earnings of -1.810/share, with the earnings report taking place on 11/4/2025. For Q2 of 2025, RARE reported earnings of -1.170/share, with the earnings report taking place on 8/5/2025. Based on these past earnings dates, the projected next earnings date for RARE is 11/3/2026 after market close.

Any self directed investor who desires to keep tabs on the companies they own, can benefit from maintaining a calendar of next earnings dates for each stock in their porfolio, such as Ultragenyx Pharmaceutical. When a company files its 10Q's with the SEC a mere four times a year, that certainly puts a lot of pressure on those four out of three hundred sixty five days! To say that earnings reports are important to Ultragenyx Pharmaceutical shareholders would thus be an understatement! That's why we started the NextEarningsDate.com website, to make it easy for self directed investors to research Ultragenyx Pharmaceutical next earnings dates as well as any other stock out there in our coverage universe, to see when the next RARE earnings date — or any other stock — falls on the calendar. But we also present considerably more than just the next earnings date information alone, so we encourage you to explore the additional pages linked above to look up RARE's past earnings as well, with pages for revenue and earnings history data, as well as earnings surprises as well. Thanks for visiting, and we hope you'll think of our site the next time you need to learn about the RARE next earnings date.